Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

Compass Pathways' COMP005 trial met its primary endpoint in TRD, but modest results sparked a 47% drop in shares amid ...

Compass Pathways’ stock has crashed by nearly 50% despite the company announcing its Phase III trial of psilocybin had met ...

Findings showed COMP360 psilocybin statistically significantly reduced symptom severity compared with placebo, as measured by MADRS.

Stifel said the plunge in Compass Pathways shares was “significantly overdone” after data showed that the company’s COMP360 met the primary endpoint in a Phase 3 trial for treatment-resistant ...

Compass Pathways' Phase 3 COMP-360 data met primary endpoints but disappointed vs analyst expectations. See why investors ...

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in ...

Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity ...

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...

An Iowa lawmaker who pushed for a bill allowing the medicinal use of psilocybin is supporting of Gov. Kim Reynold’s veto of a ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...